| Revenue growth | Consolidated FY26 grew 12.3% YoY; Standalone grew 3.8%. |
|---|---|
| Margins | Gross margin expanded 130bps in FY26 due to better product mix. |
| Demand visibility | Strong H2 momentum; 21% growth vs H1 FY26. |
| Management confidence | High; citing sustained customer engagement and pricing strategy success. |
Growth
FY26 Consolidated Revenue up 12.3% YoY to ₹1,875.3cr; Standalone PAT up 1.4% to ₹336cr.
Outlook
Strong trajectory with H1-H2 revenue growth of 21%; Capex of ₹296cr in FY26; expanding cardiology/orthopedics footprint.
Risks
Q4 consolidated EBITDA impacted by acquisition costs and one-time regulatory/employee provisions in subsidiaries.
Earnings Call filed with NSE, NSE: POLYMED. Summary written with AI assistance from the document.
Poly Medicure Ltd: key numbers
- Share price
- ₹1,724.40
- Market cap
- ₹17,479 Cr
- Revenue (annual)
- ₹1,875 Cr
- Net profit (annual)
- ₹322.1 Cr
- P/E (TTM)
- 55.5×Sector 57.8×
- Promoter holding
- 62.42%+0.00% QoQ
- FII holding
- 5.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Poly Medicure Ltd
All →Poly Medicure Annual General Meeting
Poly Medicure conducted its 31st Annual General Meeting on September 5, 2026, via video conferencing. This filing provides a summary of the meeting's proceedings and agenda items.
Poly Medicure Earnings Call Transcript: Key Takeaways
PolyMed Q1FY27 shows strong standalone margin performance beating guidance, but consolidated numbers are dragged by the Middle East crisis and pricing pressure in the renal segment from Chinese dumping.
- Call
- Guides 100% growth
Poly Medicure Investor Presentation: Key Takeaways
Poly Medicure reported strong Q1 FY27 consolidated revenue growth of 30.3% YoY, driven by acquisitions (Citieffe, PendraCare) and domestic expansion. Strategy shifts towards high-complexity medical devices like Cardiology and Orthopaedics.
- Call
- Guides 100% growth
Poly Medicure Q1 FY27 Results: Net Profit ₹85.3 Cr, Down 8.4% YoY
Poly Medicure Ltd reported revenue from operations of ₹525.4 Cr (+30.3% YoY) and net profit of ₹85.3 Cr (-8.4% YoY) for Q1 FY27.
- Key figure
- Net profit ₹85.3 Cr · -8.4% YoY
Poly Medicure Earnings Call: Key Takeaways
Poly Medicure reported FY26 consolidated revenue of ₹1,875cr (up 12.3%) and standalone EBITDA of ₹446cr (26.8% margin). The company is transitioning from product-focused to therapy-focused segments like Cardiology and Renal.
Poly Medicure Earnings Call: Key Takeaways
Poly Medicure delivered solid revenue growth despite geopolitical and raw material headwinds, successfully pivoting towards high-margin oncology, renal, and cardiology segments while integrating key acquisitions.